ASH 2020

Complete Coverage

Decitabine With Venetoclax as Salvage Therapy in R/R Acute Myeloid Leukemia

For younger patients with relapsed or refractory AML, the use of decitabine with venetoclax may be an appropriate salvage therapy, and is comparable to intensive chemotherapy regimens.

Mantle Cell Lymphoma: Long-Extending Remissions With Lenalidomide, Rituximab

Initial treatment of mantle cell lymphoma with lenalidomide and rituximab may result in significant complete response rates and durable lengths of remission.

Intensive Chemotherapy Tolerable, Efficacious in HIV-Associated Burkitt Lymphoma

Among patients with HIV-associated Burkitt lymphoma, intensive regimens containing rituximab may be linked to favorable survival outcomes.

Durable Responses Seen With Odronextamab in Refractory B-Cell NHLs

Encouraging antitumor activity and durable responses were reported with odronextamab among patients with highly refractory B-cell NHLs.

Mortality Risk in Patients With Hematologic Malignancies and COVID-19

Investigators assessed mortality rates and other outcomes in patients with hematologic malignancies and COVID-19 infection.

Does Prior TKI Therapy Affect Outcomes in R/R AML Treated With Gilteritinib?

Investigators retrospectively assessed whether previous TKI therapy may affect response and survival outcomes in patients with relapsed or refractory acute myeloid leukemia.

Older Patients With NHL Are at Higher Risk for Hospitalization vs Non-Cancer Controls

The average spending per hospitalization during the course of 5 years was higher for survivors of NHL compared with controls ($16,950 vs. $13,474).

Venetoclax in Combination With FLAG-IDA Is Efficacious in Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax in combination with fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin may benefit patients with treatment-naive or relapsed/refractory acute myeloid leukemia.

Hospitalization Burden of Patients with Multiple Myeloma

Hospitalization due to MM has increased over the last 10 years, but in-hospital mortality has declined.

Fixed Duration Ibrutinib-Venetoclax for CLL Resulted in High Rate of Undetectable MRD

Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.